Compare Paychex, Inc. (PAYX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Pfizer Inc — how do they compare? Paychex, Inc. trades at $104.29 (market cap $37.19B), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 4.3× Paychex, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Pfizer Inc for 158 Days on average.
| PAYX | PFE | |
|---|---|---|
Market Cap | $37.19B | $158.56B |
Volume | 3,344,316 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $128.59 | $29.02 |
52-Week Low | $85.57 | $23.67 |
Typical Hold Time | 56 Days | 158 Days |
Enterprise Value | $40.87B | $210.06B |
Dividend Yield | 4.56% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $101.55, up 0.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 27.35% net income margin and a 47.06% ROE, but valuation metrics like a P/E of 20.15 and P/S of 5.52 suggest a premium. Recent news highlights concerns over dividend sustainability and a 14% stock decline, even as the company reported double-digit earnings growth driven by PEO and insurance segments.
The outlook is mixed: solid fundamentals and a consensus price target of $111.00 imply upside, but bearish technicals and investor skepticism about growth levers like AI pose risks. Key opportunities include consistent dividend payments and market leadership, while risks involve labor market sensitivity and high debt levels following a significant increase in total liabilities.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
